Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oralair in Seasonal Allergic Rhinitis
NCT02014623Phase 4Completed
- Start
- Feb 2014
- Primary completion
- Nov 2019
- Modality
- Allergy Immunotherapy
- Countries
- 1
01
Overview
Phase 4, open-label trial of Oralair in allergic rhinitis (AR) (2 arms). Primary endpoint: Change from Baseline in Ryegrass specific-IgG4 at 12 months. Started Feb 2014; status: completed.
02
Drugs
Oralair
03
Conditions
allergic rhinitis (AR)
Beyond the preview
Go deeper on NCT02014623.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02014623.